The combination therapy of nivolumab and ipilimumab demonstrated favorable 5-year survival rates even in patient populations with PD-L1 tumor proportion scores of less than 1%, where PD-1/PD-L1 inhibitors are considered less effective [14]. The gene discussed is CD274; the disease is neoplasm.